2024-11-18

VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIAL OF IMM0306

2024-11-13

VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIALS OF IMM27M

2024-11-12

VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE III CLINICAL TRIAL OF IMM01 (TIMDARPACEPT) IN COMBINATION WITH AZACITIDINE FOR THE FIRST-LINE TREATMENT OF CMML

2024-11-06

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2024

2024-10-25

INSIDE INFORMATION - PROPOSED PARTICIPATION IN THE H SHARE FULL CIRCULATION PROGRAMME BY THE COMPANY

2024-10-24

VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE IB CLINICAL TRIAL OF IMM0306 FOR THE TREATMENT OF SLE

2024-10-14

LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS

2024-10-14

(1) RESIGNATION OF NON-EXECUTIVE DIRECTOR; AND (2) PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR

2024-10-07

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2024

2024-09-30

LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS

2024-09-30

(1) RESIGNATION OF NON-EXECUTIVE DIRECTOR; AND (2) PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR

2024-09-27

DISCLOSEABLE TRANSACTION - SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCT

2024-09-23

2024 Interim Report

2024-09-16

INSIDE INFORMATION - UPDATE ON GLOBAL REGISTRATIONAL STRATEGY FOR IMM2510 FOR NON-SMALL CELL LUNG CANCER AND TRIPLE-NEGATIVE BREAST CANCER

2024-09-13

VOLUNTARY ANNOUNCEMENT - TRANSFER OF EQUITY INTEREST IN A SUBSIDIARY

2024-09-11

VOLUNTARY ANNOUNCEMENT - FURTHER PAYMENT RECEIVED UNDER THE LICENSE AND COLLABORATION AGREEMENT WITH SYNBIOTX FOR IMM2510 AND IMM27M

2024-09-10

VOLUNTARY ANNOUNCEMENT - UNUSUAL PRICE MOVEMENTS

2024-09-04

Next Day Disclosure Return

2024-09-04

INSIDE INFORMATION - COMPLETION OF THE H SHARE FULL CIRCULATION BY THE COMPANY

2024-09-04

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 August 2024